One Nucleus’ ON Helix 2025 “Getting Ready for Clinic”

Pre-clinical research is often where promising science falters. In this ON Helix panel, hosted by One Nucleus, tranScrip’s Executive Medical Director, Early Development, Chris Floyd, explored how robust strategy, timely go/no-go decisions and cross-functional thinking can turn common bottlenecks into catalysts, sharpening clinical readiness, cutting costly detours and accelerating the journey from lab bench to first-in-human studies.

Together they shared practical insights on selecting the right models, de-risking pivotal studies, and aligning regulatory, manufacturing and commercial considerations early—ensuring innovative therapies reach patients sooner and with greater confidence.

Moderator

• Judit Molnar – VP Drug Discovery, NeoPhore; Board Member, One Nucleus

Panellists

• Marin Mladinic – Executive Director, PPD
• Dave Cook – Chief Scientific Officer, Quodria
• Christopher Floyd – Executive Medical Director, tranScrip
• Debra Babalola – Co-Founder & CEO, DotPlot
• Johannes Stanta – Chief Executive Officer, Bionavix